GHRP-2: What the Research Shows About This Second-Generation GH Secretagogue

What Is GHRP-2?

GHRP-2 (Growth Hormone Releasing Peptide-2, also known as pralmorelin) is a synthetic hexapeptide that stimulates growth hormone release through the ghrelin receptor (GHS-R1a). It is considered a second-generation GH secretagogue, developed after GHRP-6 with the goal of improving potency and reducing certain side effects.

GHRP-2 is one of the more extensively studied GHRPs in clinical settings. It has been used as a diagnostic tool for growth hormone deficiency in several countries (notably Japan, where it is approved for this purpose under the name pralmorelin) and has been investigated in multiple human studies examining GH secretion patterns.

Among the GH releasing peptides, GHRP-2 occupies a middle position in terms of selectivity: it produces stronger GH release per microgram than GHRP-6, with less appetite stimulation, but is less selective than ipamorelin in terms of cortisol and prolactin effects.

Who this page is for, and who it isn’t for

This page is for people who want to understand GHRP-2’s pharmacology, clinical evidence, and how it compares to other GH secretagogues. It is written for researchers and informed readers evaluating the available data.

This page is not a dosing guide or treatment recommendation. Outside of its approved diagnostic use in Japan, GHRP-2 is not approved for therapeutic use. Consult a healthcare provider for medical decisions.

How GHRP-2 Is Thought to Work

GHRP-2 activates the ghrelin receptor to stimulate pulsatile growth hormone release, with a somewhat cleaner profile than first-generation GHRPs.

Like GHRP-6, GHRP-2 works by binding the growth hormone secretagogue receptor (GHS-R1a). It stimulates GH release through both direct pituitary action and hypothalamic modulation (increasing GHRH tone and reducing somatostatin inhibition).

GHRP-2 has higher binding affinity for GHS-R1a than GHRP-6, which translates to greater GH release per unit dose. However, it still activates the receptor broadly enough to produce some cortisol and prolactin elevation, effects that are dose-dependent and generally modest at lower doses (Bowers et al., 1994).

The appetite-stimulating effect of GHRP-2 is present but considerably less pronounced than GHRP-6. This is one of its primary advantages as a second-generation compound.

When co-administered with GHRH analogs like CJC-1295 or sermorelin, GHRP-2 produces synergistic GH release, a pattern consistent across the GHRP class and well-documented in the peptide stacking literature.

What the Research Shows

GHRP-2 has more human clinical data than most GHRPs, particularly from its use as a diagnostic agent.

Growth hormone secretion (human data)

GHRP-2 is one of the most potent stimulators of GH release among the synthetic GHRPs. Bowers et al. demonstrated robust, dose-dependent GH responses in both normal and GH-deficient subjects. At equivalent doses, GHRP-2 consistently produces higher peak GH levels than GHRP-6 (Bowers et al., 1994).

In Japanese clinical studies leading to its approval as a diagnostic tool, GHRP-2 (pralmorelin) demonstrated reliable GH stimulation that proved useful for differentiating GH-deficient from GH-sufficient patients (Kojima et al., 2016).

GHRP-2 + GHRH synergy (human data)

The synergy between GHRP-2 and GHRH has been documented in human studies. Combined administration produces GH peaks substantially higher than either agent alone. This synergy is the basis for community stacking protocols combining GHRPs with GHRH analogs.

Cortisol and prolactin effects (human data)

GHRP-2 produces modest elevations in cortisol and prolactin, particularly at higher doses. These elevations are transient and generally return to baseline within 1-2 hours. The cortisol response is less pronounced than with GHRP-6 and substantially less than with hexarelin, but more than with ipamorelin, which produces minimal cortisol/prolactin changes (Arvat et al., 1997).

Body composition (limited human data)

Direct body composition studies with GHRP-2 are limited. Most inferences about body composition effects are extrapolated from the known effects of GH elevation, which, as noted in our MK-677 review, do not always translate to the dramatic recomposition effects that community discussions sometimes suggest.

Appetite and food intake (human data)

GHRP-2 does increase appetite, but the effect is generally reported as moderate, substantially less than GHRP-6 and more manageable for most users. One study demonstrated increased food intake following GHRP-2 administration, consistent with ghrelin receptor activation, though the magnitude was less than observed with GHRP-6 [research needed].

Community-Reported Protocols

The following reflects what is discussed in online communities and does not constitute medical advice. Consult a healthcare provider before using any research compound.

Community discussions typically describe subcutaneous injection of 100-300 mcg per dose, administered 2-3 times daily. Common timing includes morning (fasted), pre-workout, and before bed. As with other GHRPs, users generally administer on an empty stomach, as food (particularly fats and carbohydrates) can blunt the GH response.

GHRP-2 is frequently discussed as a “middle ground” option, more potent than GHRP-6 without the extreme hunger, but not as clean as ipamorelin. Users who find ipamorelin’s GH elevation insufficient sometimes move to GHRP-2 as the next step up.

The most common stacking protocol involves combining GHRP-2 with a GHRH analog (typically CJC-1295 without DAC or sermorelin) to take advantage of the documented synergy between these pathways.

Cycle lengths in community reports range from 8-16 weeks, with some users reporting continuous use. The long-term safety implications of sustained use at community doses have not been evaluated in controlled trials.

Side Effects and Safety Considerations

GHRP-2 generally has a more favorable side effect profile than GHRP-6 but is less selective than ipamorelin.

Commonly reported effects:

• Moderate appetite increase — present but significantly less intense than GHRP-6
• Cortisol elevation: modest and transient at typical doses, dose-dependent
• Prolactin elevation: modest and transient, may be relevant with frequent high-dose use
• Water retention: mild, consistent with GH elevation
• Tiredness around injection: transient drowsiness reported by some users
• Injection site irritation: mild, occasional

For users particularly concerned about cortisol and prolactin effects, ipamorelin offers a demonstrably cleaner profile. For those wanting the strongest possible GH pulse and willing to accept more side effects, hexarelin produces higher peaks.

The safety considerations common to all GH secretagogues apply: theoretical concerns about sustained IGF-1 elevation and cancer risk, the absence of long-term safety data at community-used doses, and the general principle that compounds not approved for therapeutic use lack the comprehensive safety monitoring of approved medications.

Related Peptides

• GHRP-6: first-generation GHRP, stronger appetite, more cortisol
• Ipamorelin: most selective GHRP, minimal side effects
• Hexarelin: strongest GH release, but desensitization
• CJC-1295: GHRH analog, synergistic with GHRPs
• MK-677: oral ghrelin mimetic, same pathway
• Sermorelin: GHRH analog, formerly FDA-approved

Frequently Asked Questions

How does GHRP-2 compare to GHRP-6?

GHRP-2 produces stronger GH release per microgram with less appetite stimulation and somewhat less cortisol/prolactin elevation. It is generally considered the improved version. The main advantage of GHRP-6 is for those who specifically want appetite stimulation.

How does GHRP-2 compare to ipamorelin?

GHRP-2 produces stronger GH release but with more cortisol and prolactin elevation. Ipamorelin is more selective (essentially “cleaner”) but may produce slightly lower peak GH levels. The choice depends on whether maximal GH stimulation or minimal side effects is the priority.

Is GHRP-2 approved anywhere?

Yes. GHRP-2 (pralmorelin) is approved in Japan as a diagnostic agent for growth hormone deficiency. It is not approved for therapeutic use (muscle growth, anti-aging, etc.) in any country.

Does GHRP-2 cause desensitization?

At standard doses used in research, significant desensitization has not been clearly demonstrated for GHRP-2. This contrasts with hexarelin, which shows measurable desensitization with repeated use. However, this has not been systematically studied at the doses and durations used in community protocols.

Can GHRP-2 be used during caloric restriction?

The moderate appetite stimulation makes it more practical than GHRP-6 during caloric restriction, though some appetite increase should be expected. Ipamorelin may be preferable for this context due to its minimal appetite effects.

References

1. Bowers CY, et al. (1994). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. PubMed

2. Arvat E, et al. (1997). Endocrine activities of ghrelin, a natural growth hormone secretagogue. J Clin Endocrinol Metab. PubMed

3. Kojima M, et al. (2016). The role of the growth hormone secretagogue receptor in the diagnosis of growth hormone deficiency. Endocr J. PubMed

4. Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. [research needed]

5. Laferrère B, et al. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. [research needed]

Related Articles

Peptide

CJC-1295: What the Evidence Says About This GHRH Analog

An evidence-first review of CJC-1295, covering how it differs from native GHRH, DAC vs no-DAC variants, clinical trial data, and what the research shows about GH stimulation.

Peptide

Hexarelin: What the Research Shows About This Potent GH Secretagogue

An evidence-based review of hexarelin, covering research on growth hormone release, cardiac effects, desensitization concerns, and comparisons to other GHRPs.

Peptide

GHRP-6: What the Research Shows About This Growth Hormone Releasing Peptide

An evidence-based review of GHRP-6, covering research on growth hormone secretion, appetite stimulation, and how it compares to newer GH secretagogues.